Efficacy and safety of microneedling-assisted topical botulinum toxin A for the treatment of enlarged facial pores: a split-face randomized controlled trial

Phase 4

• Conditions: visible topographic enlarged facial pores; enlarged facial pores

• Registration Number: TCTR20220527006
• Lead Sponsor: Department of Dermatology, Faculty of Medicine Siriraj Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-27
• Study Completion: 2023-01-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

participants with visible topographic enlarged facial pores confirmed by a dermatologist

Exclusion Criteria

1. photosensitive dermatoses, Skin malignancy, keloid, immunocompromised host, dermatitis or infection at the treatment area
2. regular smoking
3. Pregnancy and lactating woman first 3 months
4. Cannot come back for follow up
5. AHA, retinoic acid, or topical agents for acne scar within 6 months 6. Laser, RF within 3 months
7. Systemic steroid, immunosuppressive agents within 6 months
8. Oral isotretinoin within 12 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Facial pores size at 2 weeks, 1 months, 3 months and 6 months after intervention change in selected area of the facial pore size captured by Antera 3D imaging program

Secondary Outcome Measures

Name	Time	Method
Sebum production at 2 weeks, 1 months, 3 months and 6 months after intervention Change in sebum production measured by Sebumeter,Safety at 2 weeks, 1 months, 3 months and 6 months after intervention history tajing and physical examination